11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

Authors :: Rona Yaeger
Takayuki Yoshino
J.H.M. Schellens
Arkendu Chatterjee
Jason E. Faris
Sunil Sharma
Yasuhide Yamada
R. van Geel
Johanna C. Bendell
Emin Avsar
Zev A. Wainberg
Anna Spreafico
H. J. Lenz
F. Eskens
Martin Schuler
Savina Jaeger
J.-P. Delord
Tim Demuth
J. Tabernero
Martijn P. Lolkema
Source :: European Journal of Cancer. 50:199
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Cetuximab
Colorectal cancer
business.industry
Mutant
medicine.disease
Phase i study
Internal medicine
Encorafenib
medicine
In patient
business
PI3K/AKT/mTOR pathway
medicine.drug

Full Text Access

Tools